Tigecycline: A new glycylcycline for treatment of serious infections

Clinical Infectious Diseases

Volumn 41, Issue 5 SUPPL., 2005, Pages

  Noskin, Gary A ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; GLYCYLCYCLINE DERIVATIVE; IMIPENEM; LEVOFLOXACIN; MINOCYCLINE; MOXIFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; APPENDICITIS; AREA UNDER THE CURVE; BACTERIAL INFECTION; CHOLECYSTITIS; CLINICAL TRIAL; DISEASE SEVERITY; DIVERTICULITIS; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; GRAM NEGATIVE BACTERIUM; HEADACHE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MOLECULAR STRUCTURE;

EID: 23844496128     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/431672     Document Type: Review

References (63)

1. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244:379-86.
2. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36:1418-23.
3. Johnson AP, Livermore DM, Tillotson GS. Antimicrobial susceptibility of gram-positive bacteria: what's current, what's anticipated? J Hosp Infect 2001; 49(Suppl A):S3-11.
4. Bouchillon SK, Johnson BM, Hobana DJ, et al. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int J Antimicrob Agents 2004; 24:119-24.
5. Sum PE, Sum FW, Projan SJ. Recent developments in tetracycline antibiotics. Curr Pharm Des 1998; 4:119-32.
6. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001; 40:173-7.
7. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936, tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36:19-36.
8. Bauer G, Berens C, Projan SJ, Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004; 53:592-9.
9. Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr Opin Pharmacol 2001; 1:464-9.
10. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64:63-88.
11. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26:704-14.
12. Murray J, Wilson S, Klein S, Yellin A, Loh E. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a phase 2 clinical trial [abstract L-739]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003:416.
13. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000; 20:219S-23S.
14. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butyl-glycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43:738-44.
15. van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000; 44:943-9.
16. Hirata T, Saito A, Nishino K, Tamura N, Yamaguchi A. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother 2004; 48:2179-84.
17. Betriu C, Rodriguez-Avial I, Sanchez BA, Gomez M, Alvarez J, Picazo JJ. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 2002; 46: 892-5.
18. Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother 2000; 44:2747-51.
19. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47:400-4.
20. Fritsche TR, Sader HS, Kirby JT, Jones RN. In vitro activity of the glycylcycline tigecycline tested against a worldwide collection of 10,127 contemporary staphylococci, streptococci and enterococci [abstract P937]. In: Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases (Prague). Basel: European Society of Clinical Microbiology and Infectious Diseases, 2004: 246.
21. Cercenado E, Cercenado S, Gomez JA, Bouza E. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 2003; 52:138-9.
22. Low DE, Kreiswirth BN, Weiss K, Willey BM. Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus. Int J Antimicrob Agents 2002; 20:220-2.
23. Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 2000; 44:2225-9.
24. Kitzis MD, Ly A, Goldstein FW. In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2004; 48:366-7.
25. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47:1867-74.
26. Betriu C, Culebras E, Rodriguez-Avial I, Gomez M, Sanchez BA, Picazo JJ. In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance. Antimicrob Agents Chemother 2004; 48: 323-5.
27. Patel R, Rouse MS, Piper KE, Steckelberg JM. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000; 38:177-9.
28. Petersen PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 2002; 46:2595-601.
29. Gales AC, Silva JB, Andrade SS, Sader HS, Jones RN. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from the Latin American region [abstract E-1537]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003:257.
30. Deshpande LM, Gales AC, Jones RN. GAR-936 (9-t- butylglycylamidominocycline) susceptibility test development for streptococci, Haemophilus influenzae, and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria. Int J Antimicrob Agents 2001; 18:29-35.
31. Johnson B, Stevens T, Bouchillon S, et al. Tigecycline (GAR-936) a novel glycylcycline with promising anti-staphylococcal activity [abstract E-1536]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003:257.
32. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003; 52:864-8.
33. Betriu C, Rodriguez-Avial I, Sanchez BA, Gomez M, Picazo JJ. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother 2002; 50:758-9.
34. Henwood CJ, Gatward T, Warner M, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49:479-87.
35. Cercenado E, Cercenado S, Bouza E. In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates. Antimicrob Agents Chemother 2003; 47: 2644-5.
36. Johnson B, Stevens T, Bouchillon S, et al. In vitro study of tigecycline against 776 clinical isolates of non-Enterobacteriaceae from hospitals across Europe [abstract 3311]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003: 206.
37. Johnson B, Stevens T, Bouchillon S, et al. In vitro antibacterial activity of tigecycline a novel glycylcycline against clinical isolates of Enterobacteriaceae [abstract 3464]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003: 206-7.
38. Edlund C, Nord CE. In vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000; 6:159-63.
39. Wallace RJ Jr, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46:3164-7.
40. Rhomberg PR, Jones RN. In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. Diagn Microbiol Infect Dis 2002; 42:145-7.
41. Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents 2000; 16:61-3.
42. Reynolds R, Potz N, Colman M, Williams A, Livermore D, MacGowan A. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 2004; 53:1018-32.
43. Hoellman DB, Pankuch GA, Jacobs MR, Appelbaum PC. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 2000; 44:1085-8.
44. Murphy TM, Deitz JM, Petersen PJ, Mikels SM, Weiss WJ. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 2000; 44:3022-7.
45. Nannini EC, Pai SR, Singh KV, Murray BE. Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model. Antimicrob Agents Chemother 2003; 47:529-32.
46. Labthavikul P, Petersen PJ, Bradford PA. In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model. Antimicrob Agents Chemother 2003; 47:3967-9.
47. Lefort A, Lafaurie M, Massias L, et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003; 47:216-22.
48. Mercier RC, Kennedy C, Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002; 22: 1517-23.
49. Jones R, Fritsche T, Sader H, Beach M. Antimicrobial activity of tigecycline (GAR-936) tested against Enterobacteriaceae, and selected non-fermentative gram-negative bacilli, a worldwide sample [abstract P939]. In: Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases (Prague). Basel: European Society of Clinical Microbiology and Infectious Diseases, 2004: 247.
50. Zhanel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47:1875-81.
51. Sader HS, Fritsche TR, Kirby JT, Jones RN. Activity of tigecycline tested against clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Neisseria meningitidis, a worldwide perspective [abstract 940]. In: Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases (Prague). Basel: European Society of Clinical Microbiology and Infectious Diseases, 2004: 247.
52. Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003; 47:665-9.
53. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47:972-8.
54. Jacobus NV, McDermott LA, Ruthazer R, Snydman DR. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother 2004; 48:1034-6.
55. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001; 45:2604-8.
56. Edelstein PH, Weiss WJ, Edelstein MA. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2003; 47: 533-40.
57. Sesoko S, Umemura K, Nakashima M. Pharmacokinetics (PK), safety, and tolerability of tigecycline (GAR-936) in healthy Japanese males [abstract A-1403]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:22.
58. Muralidharan G, Getsy J, Mayer P, et al. Pharmacokinetics (PK), safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects [abstract 416]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999: 303.
59. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after a single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49:220-9.
60. Tombs NL. Tissue distribution of Gar-936, a broad-spectrum antibiotic, in male rats. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999:26.
61. Fang GD, Weiss WJ, Scheld WM. Comparative efficacy of GAR-936 (GAR), a novel glycylcycline, alone and in combination with vancomycin against highly penicillin-resistant Streptococcus pneumoniae (PRSP) experimental meningitis in rabbits [abstract 868]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000:51.
62. Troy SM, Muralidharan G, Micalizzi M, Mojavarian P, Salacinski L, Raible D. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936) [abstract A-43]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003:5.
63. Meagher AK, Cirincione BB, Liolios KA, Troy S, Ambrose PG. Pharmacokinetics of tigecycline in healthy adult volunteers and in subjects with renal impairment [abstract P1023]. In: Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases (Prague). Basel: European Society of Clinical Microbiology and Infectious Diseases, 2004:274.